Clinical trial NCT02890784: Dasatinib Holiday for Improved Tolerability
Official title: Treatment Optimization for Patients With Chronic Myeloid Leukemia (CML) With Treatment naïve Disease (1st Line) and Patients With Resistance or Intolerance Against Alternative Abl-Kinase Inhibitors (≥2nd Line)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Myeloid Leukemia, Chronic
Lead sponsor: University of Jena
Sponsor class: OTHER
First posted: 2016-09-07
Enrollment: 291
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (≥2nd line) (DasaHIT Trial (Dasatinib Holiday for Improved Tolerability))

Detailed description: Dasatinib is indicated in Europe for:

* Treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase
* Chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib
* Ph+ acute lymphoblastic leukemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy Compared to imatinib, dasatinib in CML achieves faster and better responses. Dasatinib is known for its selected toxicities (fluid retention, edema, pleural effusion, and hematological toxicity) requiring dose reductions or treatment interruptions; these toxicities are more frequent in the first two years of treatment. A randomized dose optimization trial for QD dosing vs. BID dosing has demonstrated non-inferiority with regards to efficacy with an improved toxicity profile. In a pilot study, analyzing patients with dasatinib toxicity, a fixed dasatinib weekend holiday allowed safe toxicity management without impairing efficacy. Furthermore the alternated schedule was also able to improve response parameters in patients that had never achieved an acceptable response prior to the onset of dasatinib holiday dosing schedule. The biological rationale for a holiday dosing schedule is that dasatinib has shown an improved cell death of CML cells even after short exposure times; this improved cell death exceeds the killing rate observed with imatinib in vitro. In summary, the reported preclinical and clinical evidence indicates that efficacy seems to require adequate dasatinib Cmax, while low Cmin (five half-lives between doses) does not impair efficacy nor induces drug resistance. It is speculated that a weekend holiday, allowing a better tolerability, would improve patients' drug adherence. The Investigators hypothesize that a dasatinib holiday schedule (5x100mg+2x0mg weekly) compared to a regular dose (7x100mg weekly) will reduce the rate of clinically significant toxicity (e.g., fluid retention, hematological toxicity, musculoskeletal pain) by 20% observed within the first two years of treatment. The Investigators also hypothesize that the dasatinib holiday schedule is non-inferior to dasatinib regular dose in achieving the European LeukemiaNet (ELN) recommended levels of response within the first 24 months.

Eligibility criteria: Inclusion Criteria:

* Male or female patients with diagnosis of CP-CML with cytogenetic confirmation of Ph+ chromosome \[t(9;22)(q34;q11)\].
* Ph negative cases or patients with variant translocations who are BCR-ABL positive in multiplex PCR4 will be also considered eligible.
* ECOG performance status ≤2.
* Age ≥ 18 years old (no upper age limit is given)
* Serum levels of potassium, magnesium and total calcium within the normal limits (≥LLN \[lower limit of normal\] and ≤ULN \[upper limit of normal\]). Correction of electrolytes' levels with supplements to meet enrolment criteria is allowed.
* AST and ALT ≤2.5 x ULN or 5.0 x ULN if considered due to leukemia
* Alkaline phosphatase ≤2.5 x ULN unless considered due to leukemia
* Total bilirubin ≤1.5 x ULN, except known Gilbert disease
* Serum creatinine ≤2 x ULN
* Written informed consent prior to any study procedures being performed.

For 1st-line patients:

• Pre-treatment with hydroxyurea up to 6 months and imatinib or dasatinib for duration of up to 4 weeks is permitted.

For ≥ 2nd-line patients:

• Patients with treatment failure according to the 2013 ELN Recommendations criteria3 or treatment intolerance as assessed by the investigator after prior treatment with TKIs other than dasatinib (imatinib, nilotinib, bosutinib, ponatinib).

Exclusion Criteria:

* Previous allogeneic stem cell transplantation (AlloSCT)
* Known impaired cardiac function, including any of the following:

  * Congenital long QT syndrome
  * History of or presence of clinically significant ventricular or atrial tachyarrhythmia
  * QTc \>450 msec on screening ECG
  * Myocardial infarction within 6 months prior to starting therapy
* Other clinical significant heart disease (e.g. unstable angina pectoris, congestive heart failure)
* Acute or chronic viral hepatitis with moderate or severe hepatic impairment (Child-Pugh scores \>6), even if controlled
* Other concurrent uncontrolled medical conditions (e.g., active or uncontrolled infections, acute or chronic liver and renal disease) that could cause unacceptable safety risks or compromise compliance with the protocol
* Impaired gastrointestinal function or disease that may alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting and diarrhea, malabsorption syndrome, small bowel resection or gastric by-pass surgery)
* Concomitant medications known to be strong inducers or inhibitors of the CYP450 isoenzyme CYP3A4
* Patients who have undergone major surgery ≤2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
* Patients who are pregnant or breastfeeding or women of reproductive potential not employing an effective method of birth control. Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to administration of dasatinib. Post-menopausal women must be amenorrheic for at least 12 months in order to be considered of non-childbearing potential. Male and female patients must agree to employ an effective method of birth control throughout the study and for up to 3 months following discontinuation of study drug
* Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory)
* Active autoimmune disorder, including autoimmune hepatitis
* Known serious hypersensitivity reactions to dasatinib
* Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention
* Patients unwilling or unable to comply with the protocol.

Primary outcomes:
measure: cumulative toxicity score
timeFrame: month 24
measure: Rate of molecular Response
timeFrame: month 24
Secondary outcomes:
measure: Quality of life assessment
timeFrame: month 24
measure: Rate of molecular Response
timeFrame: 6 and 12 months
Other outcomes:
Locations:
city: Aachen
country: Germany
facility: Uniklinik der RWTH Aachen
city: Amberg
country: Germany
facility: Gesundheitszentrum St. Marien GmbH
city: Aschaffenburg
country: Germany
facility: Gemeinschaftspraxis Dres. Klausmann
city: Berlin
country: Germany
facility: OnkoBer
city: Bielefeld
country: Germany
facility: Evangelisches Klinikum Bethel gGmbH
city: Bonn
country: Germany
facility: Universitätsklinikum Bonn
city: Bremen
country: Germany
facility: Klinikum Bremen-Mitte gGmbH
city: Chemnitz
country: Germany
facility: Klinikum Chemnitz gGmbH
city: Dresden
country: Germany
facility: Gemeinschaftspraxis Mohm/Prange-Krex
city: Dresden
country: Germany
facility: Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
city: Duisburg
country: Germany
facility: Helios St. Johannes Klinik Duisburg
city: Erlangen
country: Germany
facility: Gemeinschaftspraxis Erlangen
city: Essen
country: Germany
facility: Universitätsklinikum Essen
city: Frankfurt
country: Germany
facility: Universitätsklinikum Frankfurt
city: Freiburg
country: Germany
facility: Universitätsklinikum Freiburg
city: Goch
country: Germany
facility: Katholisches Karl-Leisner Klinikum
city: Goslar
country: Germany
facility: MVZ Onkologische Kooperation Harz
city: Göttingen
country: Germany
facility: ConMed GmbH
city: Halberstadt
country: Germany
facility: Hämato-Onkologische Gemeinschaftspraxis Halberstadt
city: Halle
country: Germany
facility: Universitätsklinikum Halle/S.
city: Hamburg
country: Germany
facility: Asklepios MVZ Onkologie
city: Hannover
country: Germany
facility: MediProjekt GbR
city: Hildesheim
country: Germany
facility: St. Bernward Krankenhaus Hildesheim
city: Jena
country: Germany
facility: Universitätsklinikum Jena
city: Kaiserslautern
country: Germany
facility: Institut für med. Dokumentation, Gutachtenstellung, Gesundheitsförderung und Qualitätssicherung GbR
city: Karlsruhe
country: Germany
facility: Städtisches Klinikum Karlsruhe gGmbH
city: Karlsruhe
country: Germany
facility: St. Vincentius-Kliniken Karlsruhe
city: Kassel
country: Germany
facility: Onkologische Gemeinschaftspraxis
city: Kassel
country: Germany
facility: Klinikum Kassel
city: Kiel
country: Germany
facility: Städtisches Krankenhaus Kiel GmbH
city: Kiel
country: Germany
facility: Universitätsklinikum Schleswig-Holstein
city: Koblenz
country: Germany
facility: InVo Institut für Versorgungsforschung
city: Krefeld
country: Germany
facility: MVZ Hämatologie und Onkologie
city: Kronach
country: Germany
facility: Onkologische Schwerpunktpraxis
city: Lebach
country: Germany
facility: Onkologisches Zentrum
city: Leer
country: Germany
facility: Studienzentrum UnterEms
city: Leipzig
country: Germany
facility: Universitätsklinikum Leipzig
city: Mannheim
country: Germany
facility: Universitätsmedizin Mannheim
city: Marburg
country: Germany
facility: Universitätsklinikum Gießen und Marburg GmbH
city: Mutlangen
country: Germany
facility: Stauferklinikum Schwäbisch Gmünd
city: München
country: Germany
facility: Rotkreuzklinikum München
city: München
country: Germany
facility: Gemeinschaftspraxis Hämatologie/ Onkologie
city: Münster
country: Germany
facility: Universitätsklinikum Münster
city: Neustadt Am Rübenberge
country: Germany
facility: Hämatologisch-onkologische Schwerpunktpraxis
city: Passau
country: Germany
facility: Klinikum Passau
city: Reutlingen
country: Germany
facility: Kreiskliniken Reutlingen GmbH
city: Rostock
country: Germany
facility: Universitätsmedizin Rostock
city: Rostock
country: Germany
facility: Klinikum Südstadt Rostock
city: Stolberg
country: Germany
facility: Hämatologie-Onkologie Stolberg
city: Trier
country: Germany
facility: Klinikum Mutterhaus der
city: Ulm
country: Germany
facility: Universitätsklinikum Ulm
city: Villingen-Schwenningen
country: Germany
facility: Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH
city: Winnenden
country: Germany
facility: Rems-Murr-Klinik Winnenden
Study officials:
affiliation: Jena University Hospital
name: Andreas Hochhaus, Prof.
role: PRINCIPAL_INVESTIGATOR
References: